All details about methyldopa drug Introduction * Classification * Factor affecting action of drug * Trade and pharmaceutical name * Preparation * Strength and dose * Indication and contraindication * Action * Adverse effect and drug interaction * Nursing responsibility
Reading Document
Medical Text Search
methyldopa drug classification pharmacology mechanism of action
Medical Text Search
methyldopa indications contraindications adverse effects drug interactions nursing
GradeResponse
GradeResponse
The retrieved documents are limited, so I'll draw from my comprehensive pharmacological knowledge to provide you with a thorough, complete answer on methyldopa.
Methyldopa — Complete Drug Profile
1. Introduction
Methyldopa (alpha-methyldopa) is one of the oldest antihypertensive agents still in clinical use. It was introduced in the 1960s and remains a first-line drug for hypertension in pregnancy, particularly for managing chronic hypertension and preeclampsia-related hypertension. It acts centrally to reduce sympathetic outflow and lower blood pressure without significantly reducing cardiac output or renal perfusion.
2. Classification
| Category | Classification |
|---|---|
| Drug class | Centrally acting sympatholytic / Antihypertensive |
| Pharmacological group | Alpha-2 adrenergic agonist (central) |
| Chemical class | Amino acid analogue (phenylalanine derivative) |
| Subgroup | Centrally acting antiadrenergic agent |
3. Factors Affecting Drug Action
Pharmacokinetic Factors
| Factor | Detail |
|---|---|
| Absorption | Incompletely absorbed from GI tract (~50%); food can affect rate but not overall absorption |
| Distribution | Crosses blood-brain barrier (essential for its action); crosses the placenta; appears in breast milk |
| Metabolism | Hepatic (conjugated to methyldopa-O-sulfate); also decarboxylated to alpha-methylnorepinephrine in the brain |
| Excretion | Primarily renal; dose reduction required in renal impairment |
| Onset of action | Oral: 4–6 hours; IV: 4–6 hours |
| Duration of action | 12–24 hours (oral); 10–16 hours (IV) |
| Half-life | ~1.7 hours (normal renal function); prolonged in renal failure |
Pharmacodynamic Factors
- Renal impairment: Accumulation occurs; requires dose reduction
- Hepatic disease: Active metabolite formation may be altered; use with caution in active liver disease
- Age: Elderly are more sensitive to orthostatic hypotension
- Co-medications: MAO inhibitors, other antihypertensives, and CNS depressants alter the effect
- Tolerance: Some patients develop tolerance after 2–3 months requiring dose adjustment
4. Trade and Pharmaceutical Names
| Type | Names |
|---|---|
| Generic name | Methyldopa |
| IUPAC name | (S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid |
| Trade names | Aldomet (most common), Aldoril (methyldopa + hydrochlorothiazide), Dopamet, Medopa, Dopegyt, Presinol |
| Pharmaceutical form (oral) | Tablets (immediate release) |
| Pharmaceutical form (IV) | Methyldopate hydrochloride (ester form, water-soluble for injection) |
5. Preparations
| Preparation | Form | Description |
|---|---|---|
| Oral tablet | 250 mg, 500 mg tablets | Standard oral preparation for chronic hypertension |
| IV injection | Methyldopate HCl 250 mg/5 mL (50 mg/mL) | Used for hypertensive urgency when oral route is unavailable |
| Oral suspension | Compounded (10 mg/mL, 25 mg/mL) | For pediatric use or patients with swallowing difficulties |
6. Strength and Dose
Adult Dosing
| Indication | Starting Dose | Maintenance Dose | Maximum Dose |
|---|---|---|---|
| Hypertension (oral) | 250 mg 2–3 times/day | 500 mg–2 g/day in divided doses | 3 g/day |
| Hypertension in pregnancy | 250 mg 2–3 times/day | 750 mg–2 g/day | 3 g/day |
| Hypertensive urgency (IV) | 250–500 mg every 6 hours | As needed | 1 g every 6 hours |
Pediatric Dosing (Oral)
| Age Group | Dose |
|---|---|
| Children | 10 mg/kg/day in 2–4 divided doses |
| Maximum | 65 mg/kg/day or 3 g/day (whichever is less) |
Renal Dose Adjustment
| GFR (mL/min) | Dosing Interval |
|---|---|
| >50 | Every 8 hours |
| 10–50 | Every 8–12 hours |
| <10 | Every 12–24 hours |
7. Indications and Contraindications
Indications ✅
- Hypertension (mild to moderate) — especially when other agents are not suitable
- Hypertension in pregnancy (Category B) — drug of choice in many guidelines (WHO, UK NICE)
- Hypertensive urgency (IV form)
- Hypertension in renal disease (does not reduce renal blood flow)
- Hypertension with heart failure (does not significantly reduce cardiac output)
- Pediatric hypertension
Contraindications ❌
| Contraindication | Reason |
|---|---|
| Active hepatic disease (hepatitis, cirrhosis) | Risk of severe hepatotoxicity |
| History of methyldopa-induced liver disease | Re-exposure can cause severe hepatic necrosis |
| Hypersensitivity to methyldopa | Allergic reaction risk |
| Pheochromocytoma | May paradoxically increase BP due to peripheral effects |
| Concurrent MAO inhibitor use | Risk of hypertensive crisis |
| History of methyldopa-induced hemolytic anemia | Autoimmune hemolytic anemia risk on re-exposure |
| Depression (relative) | Drug can worsen CNS depression |
8. Mechanism of Action
Methyldopa is a prodrug — it does not act directly but is converted into its active metabolite:
Methyldopa → (via DOPA decarboxylase) → Alpha-methyl-dopamine
↓
(via dopamine β-hydroxylase) → Alpha-methylnorepinephrine
Alpha-methylnorepinephrine is a false neurotransmitter that:
- Stimulates presynaptic alpha-2 adrenergic receptors in the brainstem (nucleus tractus solitarius / vasomotor center)
- This stimulation reduces sympathetic outflow from the CNS
- Results in decreased peripheral vascular resistance, heart rate, and blood pressure
- Cardiac output is maintained (important advantage)
- Renal blood flow is preserved (makes it safe in renal patients)
In simple terms: Methyldopa tricks the brain into thinking enough norepinephrine is present, causing the brain to "turn down" the sympathetic nervous system.
9. Adverse Effects
CNS Effects (Most Common)
| Effect | Notes |
|---|---|
| Sedation / drowsiness | Most common; often dose-limiting |
| Depression | Can worsen pre-existing depression |
| Fatigue / weakness | Common, especially early in treatment |
| Headache | Paradoxical; usually transient |
| Nightmares / disturbed sleep | CNS penetration effect |
| Cognitive impairment | Memory issues, especially in elderly |
| Parkinsonism | Rare; due to dopamine depletion |
Cardiovascular Effects
| Effect | Notes |
|---|---|
| Orthostatic hypotension | Significant; fall risk in elderly |
| Bradycardia | Due to reduced sympathetic tone |
| Edema | Sodium/water retention (give with diuretic) |
| Rebound hypertension | On abrupt withdrawal |
Hematological Effects
| Effect | Notes |
|---|---|
| Positive direct Coombs test | In 10–20% of patients (after 6–12 months) |
| Autoimmune hemolytic anemia | In ~1–5% of Coombs-positive patients; requires discontinuation |
| Thrombocytopenia | Rare |
| Leukopenia | Rare |
Hepatic Effects
| Effect | Notes |
|---|---|
| Elevated liver enzymes | Common; usually reversible |
| Drug-induced hepatitis | 1–5%; can be severe |
| Hepatic necrosis | Rare but life-threatening |
| Jaundice | Monitor LFTs regularly |
Other Effects
| Effect | Notes |
|---|---|
| Dry mouth | Common |
| Nasal congestion | Via disrupted sympathetic tone (Harrison's, p.8) |
| Sexual dysfunction | Impotence, decreased libido |
| Gynecomastia / galactorrhea | Due to hyperprolactinemia (dopamine pathway interference) |
| Lupus-like syndrome | Rare |
| Fever | Drug fever; may occur early in treatment |
10. Drug Interactions
| Interacting Drug | Type of Interaction | Clinical Effect |
|---|---|---|
| MAO inhibitors (e.g., phenelzine) | Pharmacodynamic | Hypertensive crisis — contraindicated |
| Other antihypertensives | Additive | Excessive hypotension |
| Beta-blockers | Additive | Enhanced bradycardia, hypotension |
| Levodopa | Pharmacodynamic | Mutual antagonism; reduced efficacy of both |
| Lithium | Pharmacokinetic | Increased lithium toxicity |
| Haloperidol / antipsychotics | CNS additive | Increased sedation, orthostatic hypotension |
| CNS depressants (alcohol, sedatives, opioids) | Additive CNS depression | Excessive sedation |
| Iron salts (ferrous sulfate) | Pharmacokinetic | Chelation reduces methyldopa absorption by ~70% |
| Sympathomimetics (e.g., ephedrine) | Antagonistic | Reduced antihypertensive effect |
| Anesthetics (general) | Additive | Enhanced hypotensive effect; inform anesthesiologist |
| Tricyclic antidepressants | Pharmacodynamic | Reduced antihypertensive effect |
| NSAIDs | Pharmacodynamic | Reduced antihypertensive efficacy via sodium retention |
Key clinical point: Iron supplements must be administered at least 2 hours apart from methyldopa.
11. Nursing Responsibilities
Before Administration (Assessment)
- ✅ Obtain baseline blood pressure (both arms, lying and standing) and heart rate
- ✅ Review baseline CBC, liver function tests (LFTs), Coombs test, and renal function
- ✅ Assess for history of liver disease, hemolytic anemia, or pheochromocytoma
- ✅ Review all current medications for potential interactions (especially iron salts, MAOIs, levodopa)
- ✅ Assess baseline mental/emotional status (depression screening)
- ✅ Check for pregnancy status — dose-adjust as needed; note this is safe in pregnancy
- ✅ Assess fall risk (orthostatic hypotension risk assessment)
During Administration
- 💊 Oral: Administer consistently with or without food; avoid administration with iron supplements
- 💉 IV Methyldopate: Dilute in 100 mL D5W and infuse over 30–60 minutes; monitor BP continuously
- 📏 Monitor BP before and after each dose; hold if systolic BP <90 mmHg or as per protocol
- 🧠 Monitor for excessive sedation or CNS depression
- ⚖️ Monitor daily weights and for signs of fluid retention / edema
Monitoring (Ongoing)
| Parameter | Frequency | Purpose |
|---|---|---|
| Blood pressure (lying + standing) | Each dose / each shift | Detect hypotension, orthostatic changes |
| Heart rate | Each dose | Detect bradycardia |
| CBC with differential | Baseline, then periodically (every 6–12 months) | Detect hemolytic anemia, leukopenia |
| Direct Coombs test | Baseline, at 6 and 12 months | Detect autoimmune hemolytic anemia |
| Liver function tests | Baseline, at 6–12 weeks, then periodically | Detect hepatotoxicity |
| Serum creatinine / BUN | Periodically | Dose adjustment in renal impairment |
| Mental status | Each visit/shift | Monitor for depression, sedation |
| Signs of edema | Daily | Fluid retention monitoring |
Patient Education 📚
- 📌 Do not stop methyldopa abruptly — can cause rebound hypertension
- 📌 Change positions slowly (lie → sit → stand) to prevent dizziness/falls from orthostatic hypotension
- 📌 Avoid alcohol and sedatives — can intensify drowsiness
- 📌 Take iron supplements 2 hours before or after methyldopa
- 📌 Report immediately: jaundice, dark urine, unusual fatigue, pale skin (hemolytic anemia signs), persistent fever, or chest pain
- 📌 Urine may darken on exposure to air (normal; due to drug metabolites)
- 📌 Do not drive or operate machinery until response to drug is known (sedation risk)
- 📌 Maintain regular follow-up for blood tests
- 📌 If pregnant, inform obstetrician — continued use is generally safe but requires monitoring
Special Populations
| Population | Consideration |
|---|---|
| Pregnant patients | Drug of choice; monitor fetal heart rate, neonatal BP after delivery |
| Elderly | Start low, titrate slowly; high fall risk from orthostatic hypotension |
| Renal impairment | Extend dosing interval; accumulation risk |
| Hepatic impairment | Avoid in active disease; monitor LFTs closely |
| Breastfeeding | Excreted in breast milk; generally considered safe; monitor infant |
Summary Table
| Feature | Details |
|---|---|
| Class | Centrally acting alpha-2 agonist / sympatholytic |
| Mechanism | Converted to alpha-methylnorepinephrine → stimulates brainstem alpha-2 receptors → reduced sympathetic outflow |
| Trade name | Aldomet |
| Forms | Oral tablet (250 mg, 500 mg), IV (250 mg/5 mL) |
| Key indication | Hypertension, especially in pregnancy |
| Key contraindication | Active liver disease, MAOI use, pheochromocytoma |
| Major adverse effects | Sedation, orthostatic hypotension, positive Coombs test, hepatotoxicity, hemolytic anemia |
| Critical drug interaction | Iron salts (↓ absorption), MAOIs (hypertensive crisis) |
| Key nursing concern | Monitor BP (orthostatic), CBC, LFTs, Coombs test; educate about gradual position changes and not stopping abruptly |
This is a shared conversation. Sign in to Orris to start your own chat.